Generex Biotechnology (GNBT) Stock Price, News & Analysis

Company Overview

Generex Biotechnology Corporation is a biotechnology company that has historically focused on developing drug-delivery technologies, particularly systems designed to administer therapeutics through the lining of the mouth. Its proprietary RapidMist platform was developed to deliver drugs as a fine spray to the buccal mucosa, with the goal of offering an alternative to injections or conventional oral dosing.

The company’s best-known product candidate was Oral-lyn, an orally administered insulin formulation developed for people with diabetes. Generex also pursued applications of its delivery technology for vaccines and other pharmaceutical products, including through licensing, partnerships and development programs in international markets. The company has additionally been associated with immunotherapy and oncology research through affiliated operations.

Generex was historically led by Joseph Moscato, who served as chief executive officer during much of the company’s development of its drug-delivery and immunotherapy programs. Publicly available information about the company’s current operations, product commercialization and geographic activities is limited, and many of its reported programs are historical rather than descriptions of currently marketed products.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 60,924 shs
• Market Capitalization: $73 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/06/2026
• Fiscal Year End: 7/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:GNBT
• CIK: 1059784
• Web: www.generex.com
• Phone: (416) 364-2551
• Fax: 64-7547-7104
• Employees: 15
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $2.66 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 122,058,000
• Free Float: 79,094,000
• Market Cap: $73 thousand
• Optionable: Not Optionable
• Beta: -0.07